Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: A meta-analysis

Table 1 Characteristics of trials included in meta-analysis

Study	Patients (S-1/capecitabine)	S-1 regimen	Capecitabine regimen
Kim et al[23]	65/64	S-1 80 mg/m2 per day d1-14 + oxaliplatin 130 mg/m2 d1 21-d cycle	Capecitabine 2000 mg/m2 per day d1-14 + oxaliplatin 130 mg/m2 d1 21-d cycle
Lee et al[22]	42/44	S-1: BSA < 1.25 m2, 80 mg/d;	Capecitabine
		BSA: 1.25-1.5 m2, 100 mg/d;	2500 mg/m2 per day
		BSA > 1.5 m2, 120 mg/d; d1-28 42-d cycle	d1-14 21-d cycle
Zhang et al[21]	41/40	S-1 80 mg/m2 per day d1-14 + oxaliplatin 130 mg/m2 d1 21-d cycle	Capecitabine 2000 mg/m2 per day d1-14 + oxaliplatin 130 mg/m2 d1 21-d cycle
Xiong et al[20]	42/44	S-1 80 mg/m2 per day d1-14 + docetaxel 25 mg/m2 d1, 8, 15 28-d cycle	Capecitabine 1250 mg/m2 per day d1-14 + docetaxel 25 mg/m2 d1, 8, 15 28-d cycle